OBJECTIVES: We assessed retention and predictors of attrition (recorded death or loss to follow-up) in antiretroviral treatment (ART) clinics in Tanzania, Uganda and Zambia. METHODS: We conducted a retrospective cohort study among adults (≥18 years) starting ART during 2003-2010. We purposefully selected six health facilities per country and randomly selected 250 patients from each facility. Patients who visited clinics at least once during the 90 days before data abstraction were defined as retained. Data on individual and programme level risk factors for attrition were obtained through chart review and clinic manager interviews. Kaplan-Meier curves for retention across sites were created. Predictors of attrition were assessed using a multivariable Cox-proportional hazards model, adjusted for site-level clustering. RESULTS: From 17 facilities, 4147 patients were included. Retention ranged from 52.0% to 96.2% at 1 year to 25.8%-90.4% at 4 years. Multivariable analysis of ART initiation characteristics found the following independent risk factors for attrition: younger age [adjusted hazard ratio (aHR) and 95% confidence interval (95%CI) = 1.30 (1.14-1.47)], WHO stage 4 ([aHR (95% CI): 1.56 (1.29-1.88)], >10% bodyweight loss [aHR (95%CI) = 1.17 (1.00-1.38)], poor functional status [ambulatory aHR (95%CI) = 1.29 (1.09-1.54); bedridden aHR1.54 (1.15-2.07)], and increasing years of clinic operation prior to ART initiation in government facilities [aHR (95%CI) = 1.17 (1.10-1.23)]. Patients with higher CD4 cell count were less likely to experience attrition [aHR (95%CI) = 0.88 (0.78-1.00)] for every log (tenfold) increase. Sites offering community ART dispensing [aHR (95%CI) = 0.55 (0.30-1.01) for women; 0.40 (0.21-0.75) for men] had significantly less attrition. CONCLUSIONS: Patient retention to an individual programme worsened over time especially among males, younger persons and those with poor clinical indicators. Community ART drug dispensing programmes could improve retention.
OBJECTIVES: We assessed retention and predictors of attrition (recorded death or loss to follow-up) in antiretroviral treatment (ART) clinics in Tanzania, Uganda and Zambia. METHODS: We conducted a retrospective cohort study among adults (≥18 years) starting ART during 2003-2010. We purposefully selected six health facilities per country and randomly selected 250 patients from each facility. Patients who visited clinics at least once during the 90 days before data abstraction were defined as retained. Data on individual and programme level risk factors for attrition were obtained through chart review and clinic manager interviews. Kaplan-Meier curves for retention across sites were created. Predictors of attrition were assessed using a multivariable Cox-proportional hazards model, adjusted for site-level clustering. RESULTS: From 17 facilities, 4147 patients were included. Retention ranged from 52.0% to 96.2% at 1 year to 25.8%-90.4% at 4 years. Multivariable analysis of ART initiation characteristics found the following independent risk factors for attrition: younger age [adjusted hazard ratio (aHR) and 95% confidence interval (95%CI) = 1.30 (1.14-1.47)], WHO stage 4 ([aHR (95% CI): 1.56 (1.29-1.88)], >10% bodyweight loss [aHR (95%CI) = 1.17 (1.00-1.38)], poor functional status [ambulatory aHR (95%CI) = 1.29 (1.09-1.54); bedridden aHR1.54 (1.15-2.07)], and increasing years of clinic operation prior to ART initiation in government facilities [aHR (95%CI) = 1.17 (1.10-1.23)]. Patients with higher CD4 cell count were less likely to experience attrition [aHR (95%CI) = 0.88 (0.78-1.00)] for every log (tenfold) increase. Sites offering community ART dispensing [aHR (95%CI) = 0.55 (0.30-1.01) for women; 0.40 (0.21-0.75) for men] had significantly less attrition. CONCLUSIONS:Patient retention to an individual programme worsened over time especially among males, younger persons and those with poor clinical indicators. Community ART drug dispensing programmes could improve retention.
Authors: Michael L Rich; Ann C Miller; Peter Niyigena; Molly F Franke; Jean Bosco Niyonzima; Adrienne Socci; Peter C Drobac; Massudi Hakizamungu; Alishya Mayfield; Robert Ruhayisha; Henry Epino; Sara Stulac; Corrado Cancedda; Adolph Karamaga; Saleh Niyonzima; Chase Yarbrough; Julia Fleming; Cheryl Amoroso; Joia Mukherjee; Megan Murray; Paul Farmer; Agnes Binagwaho Journal: J Acquir Immune Defic Syndr Date: 2012-03-01 Impact factor: 3.731
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens Journal: Ann Intern Med Date: 2007-04-17 Impact factor: 25.391
Authors: Elvin H Geng; Denis Nash; Andrew Kambugu; Yao Zhang; Paula Braitstein; Katerina A Christopoulos; Winnie Muyindike; Mwebesa Bosco Bwana; Constantin T Yiannoutsos; Maya L Petersen; Jeffrey N Martin Journal: Curr HIV/AIDS Rep Date: 2010-11 Impact factor: 5.071
Authors: Margaret May; Andrew Boulle; Sam Phiri; Eugene Messou; Landon Myer; Robin Wood; Olivia Keiser; Jonathan A C Sterne; Francois Dabis; Matthias Egger Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Kara K Wools-Kaloustian; John E Sidle; Henry M Selke; Rajesh Vedanthan; Emmanuel K Kemboi; Lillian J Boit; Viola T Jebet; Aaron E Carroll; William M Tierney; Sylvester Kimaiyo Journal: J Int AIDS Soc Date: 2009-09-29 Impact factor: 5.396
Authors: Lillian B Brown; Diane V Havlir; James Ayieko; Florence Mwangwa; Asiphas Owaraganise; Dalsone Kwarisiima; Vivek Jain; Theodore Ruel; Tamara Clark; Gabriel Chamie; Elizabeth A Bukusi; Craig R Cohen; Moses R Kamya; Maya L Petersen; Edwin D Charlebois Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Julie A Denison; Olivier Koole; Sharon Tsui; Joris Menten; Kwasi Torpey; Eric van Praag; Ya Diul Mukadi; Robert Colebunders; Andrew F Auld; Simon Agolory; Jonathan E Kaplan; Modest Mulenga; Gideon P Kwesigabo; Fred Wabwire-Mangen; David R Bangsberg Journal: AIDS Date: 2015-01-28 Impact factor: 4.177
Authors: Paola Magro; Carlo Cerini; Aldorada da Gloria; Stelio Tembe; Francesco Castelli; Lina Rachele Tomasoni Journal: Trop Med Int Health Date: 2021-09-12 Impact factor: 3.918
Authors: Jaysingh Brijkumar; Johnathan A Edwards; Brent A Johnson; Claudia Ordonez; Henry Sunpath; Mitch Lee; Mathew R Dudgeon; Lydia Rautman; Selvan Pillay; Pravi Moodley; Y V Sun; José Castillo-Mancilla; Jonathan Z Li; Daniel R Kuritzkes; Mohamed Y S Moosa; Vincent Charles Marconi Journal: HIV Med Date: 2022-01-12 Impact factor: 3.094
Authors: Andrew F Auld; Charity Alfredo; Eugenia Macassa; Kebba Jobarteh; Ray W Shiraishi; Emilia D Rivadeneira; James Houston; Thomas J Spira; Tedd V Ellerbrock; Paula Vaz Journal: Pediatr Infect Dis J Date: 2015-08 Impact factor: 2.129
Authors: Jonathan Colasanti; Darius McDaniel; Brent Johnson; Carlos Del Rio; Henry Sunpath; Vincent C Marconi Journal: AIDS Res Hum Retroviruses Date: 2015-12-09 Impact factor: 2.205
Authors: Becky L Genberg; Juddy Wachira; Jon A Steingrimsson; Sonak Pastakia; Dan N Tina Tran; Jamil AbdulKadir Said; Paula Braitstein; Joseph W Hogan; Rajesh Vedanthan; Suzanne Goodrich; Catherine Kafu; Marta Wilson-Barthes; Omar Galárraga Journal: BMJ Open Date: 2021-05-18 Impact factor: 3.006
Authors: Sharon Tsui; Caitlin E Kennedy; Lawrence H Moulton; Larry W Chang; Jason E Farley; Kwasi Torpey; Eric van Praag; Olivier Koole; Nathan Ford; Fred Wabwire-Mangen; Julie A Denison Journal: Trop Med Int Health Date: 2021-08-08 Impact factor: 2.622
Authors: Vivek Jain; Wei Chang; Dathan M Byonanebye; Asiphas Owaraganise; Ellon Twinomuhwezi; Gideon Amanyire; Douglas Black; Elliot Marseille; Moses R Kamya; Diane V Havlir; James G Kahn Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240